ProBioGen Announces Exclusive Licensing Agreement for its Proprietary Avian Cell Line AGE1.CR
Significant upfront and milestone payments plus royalties for four indications
"This licensing agreement demonstrates the attractiveness of our unique cell line," said Michael Schlenk, CEO of ProBioGen. "We have shown that AGE1.CR is a superior vaccine production system compared to classical approaches such as egg-based production methods and other cell lines. Moreover, this agreement is another landmark in our strategy to increasingly focus on proprietary products, which are key value drivers in the context of international development collaborations."
AGE1.CR has been developed by ProBioGen to replace embryonated chicken eggs and chicken embryonic fibroblasts as substrates for production of human and animal vaccines. Primary chicken material has many disadvantages: It must be isolated freshly from specific pathogen free (SPF) flocks for each manufacturing run.
Organizations
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.